JP2011526295A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011526295A5 JP2011526295A5 JP2011516650A JP2011516650A JP2011526295A5 JP 2011526295 A5 JP2011526295 A5 JP 2011526295A5 JP 2011516650 A JP2011516650 A JP 2011516650A JP 2011516650 A JP2011516650 A JP 2011516650A JP 2011526295 A5 JP2011526295 A5 JP 2011526295A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- compound
- alkyl
- hydrogen
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 127
- -1 nitro, benzimidazolyl Chemical group 0.000 claims description 61
- 229910052739 hydrogen Inorganic materials 0.000 claims description 54
- 239000001257 hydrogen Substances 0.000 claims description 54
- 125000000217 alkyl group Chemical group 0.000 claims description 42
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 28
- 150000002431 hydrogen Chemical class 0.000 claims description 26
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 23
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 23
- 125000001424 substituent group Chemical group 0.000 claims description 20
- 229910052736 halogen Inorganic materials 0.000 claims description 18
- 150000002367 halogens Chemical class 0.000 claims description 18
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 16
- 125000006413 ring segment Chemical group 0.000 claims description 15
- 125000003118 aryl group Chemical group 0.000 claims description 14
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 13
- 125000001072 heteroaryl group Chemical group 0.000 claims description 13
- 125000005112 cycloalkylalkoxy group Chemical group 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 125000005605 benzo group Chemical group 0.000 claims description 9
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 9
- 229910052757 nitrogen Inorganic materials 0.000 claims description 9
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims description 9
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 7
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 208000008589 Obesity Diseases 0.000 claims description 5
- 235000020824 obesity Nutrition 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- 208000023105 Huntington disease Diseases 0.000 claims description 3
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 3
- 230000002996 emotional effect Effects 0.000 claims description 3
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 3
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 3
- 201000000980 schizophrenia Diseases 0.000 claims description 3
- 230000000698 schizophrenic effect Effects 0.000 claims description 3
- XTFIVUDBNACUBN-UHFFFAOYSA-N 1,3,5-trinitro-1,3,5-triazinane Chemical compound [O-][N+](=O)N1CN([N+]([O-])=O)CN([N+]([O-])=O)C1 XTFIVUDBNACUBN-UHFFFAOYSA-N 0.000 claims description 2
- 208000030814 Eating disease Diseases 0.000 claims description 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 2
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims description 2
- 208000015114 central nervous system disease Diseases 0.000 claims description 2
- 235000014632 disordered eating Nutrition 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- 230000003274 myotonic effect Effects 0.000 claims description 2
- 201000003631 narcolepsy Diseases 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 208000012201 sexual and gender identity disease Diseases 0.000 claims description 2
- 208000015891 sexual disease Diseases 0.000 claims description 2
- 208000019116 sleep disease Diseases 0.000 claims description 2
- 206010034158 Pathological gambling Diseases 0.000 claims 1
- 125000005873 benzo[d]thiazolyl group Chemical group 0.000 claims 1
- 125000006588 heterocycloalkylene group Chemical group 0.000 claims 1
- 125000005956 isoquinolyl group Chemical group 0.000 claims 1
- 230000000391 smoking effect Effects 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 description 14
- 125000000000 cycloalkoxy group Chemical group 0.000 description 10
- 125000002950 monocyclic group Chemical group 0.000 description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 6
- 125000003282 alkyl amino group Chemical group 0.000 description 5
- 125000004663 dialkyl amino group Chemical group 0.000 description 5
- 125000005842 heteroatom Chemical group 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 125000004001 thioalkyl group Chemical group 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 2
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- 125000004863 4-trifluoromethoxyphenyl group Chemical group [H]C1=C([H])C(OC(F)(F)F)=C([H])C([H])=C1* 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- CKUAXEQHGKSLHN-UHFFFAOYSA-N [C].[N] Chemical compound [C].[N] CKUAXEQHGKSLHN-UHFFFAOYSA-N 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 125000005083 alkoxyalkoxy group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- KPUFNLPDWGSMGZ-UHFFFAOYSA-N carboxy(nitro)azanide Chemical group OC(=O)[N-][N+]([O-])=O KPUFNLPDWGSMGZ-UHFFFAOYSA-N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000005553 heteroaryloxy group Chemical group 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- CSJDCSCTVDEHRN-UHFFFAOYSA-N methane;molecular oxygen Chemical compound C.O=O CSJDCSCTVDEHRN-UHFFFAOYSA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 150000002828 nitro derivatives Chemical class 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 230000005586 smoking cessation Effects 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7559408P | 2008-06-25 | 2008-06-25 | |
| US61/075,594 | 2008-06-25 | ||
| US10916208P | 2008-10-28 | 2008-10-28 | |
| US61/109,162 | 2008-10-28 | ||
| US13886608P | 2008-12-18 | 2008-12-18 | |
| US61/138,866 | 2008-12-18 | ||
| US17641309P | 2009-05-07 | 2009-05-07 | |
| US61/176,413 | 2009-05-07 | ||
| PCT/US2009/048617 WO2009158473A1 (en) | 2008-06-25 | 2009-06-25 | 5- and 6-membered heterocyclic compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011526295A JP2011526295A (ja) | 2011-10-06 |
| JP2011526295A5 true JP2011526295A5 (https=) | 2012-08-09 |
Family
ID=41119866
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011516574A Expired - Fee Related JP5658664B2 (ja) | 2008-06-25 | 2009-06-24 | １，２−二置換複素環式化合物 |
| JP2011516650A Pending JP2011526295A (ja) | 2008-06-25 | 2009-06-25 | ５員および６員複素環化合物 |
| JP2014241945A Expired - Fee Related JP5820921B2 (ja) | 2008-06-25 | 2014-11-28 | １，２−二置換複素環式化合物 |
| JP2015197316A Pending JP2016014061A (ja) | 2008-06-25 | 2015-10-05 | １，２−二置換複素環式化合物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011516574A Expired - Fee Related JP5658664B2 (ja) | 2008-06-25 | 2009-06-24 | １，２−二置換複素環式化合物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014241945A Expired - Fee Related JP5820921B2 (ja) | 2008-06-25 | 2014-11-28 | １，２−二置換複素環式化合物 |
| JP2015197316A Pending JP2016014061A (ja) | 2008-06-25 | 2015-10-05 | １，２−二置換複素環式化合物 |
Country Status (11)
| Country | Link |
|---|---|
| US (7) | US8071595B2 (https=) |
| EP (2) | EP2297133B1 (https=) |
| JP (4) | JP5658664B2 (https=) |
| KR (2) | KR20110031355A (https=) |
| CN (2) | CN102131801B (https=) |
| AU (2) | AU2009262241B2 (https=) |
| BR (2) | BRPI0914772A2 (https=) |
| CA (2) | CA2729259A1 (https=) |
| MX (2) | MX2011000175A (https=) |
| TW (2) | TWI458723B (https=) |
| WO (2) | WO2009158393A1 (https=) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2726588C (en) | 2008-06-03 | 2019-04-16 | Karl Kossen | Compounds and methods for treating inflammatory and fibrotic disorders |
| CN102131801B (zh) | 2008-06-25 | 2015-04-08 | 福拉姆医药股份有限公司 | 1,2-二取代的杂环化合物 |
| KR101662699B1 (ko) * | 2009-05-07 | 2016-10-05 | 포럼 파마슈티칼즈 인크. | 페녹시메틸 헤테로고리 화합물 |
| UY32730A (es) | 2009-06-26 | 2011-01-31 | Novartis Ag | Inhibidores de cyp17 |
| US8883788B2 (en) | 2010-08-04 | 2014-11-11 | Takeda Pharmaceutical Company Limited | Fused heterocyclic ring compound |
| EP2601192B1 (en) * | 2010-08-04 | 2017-03-01 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds |
| RU2603140C2 (ru) | 2010-09-20 | 2016-11-20 | Айронвуд Фармасьютикалз, Инк. | Соединения имидазотриазинона |
| CN107141309A (zh) | 2011-01-11 | 2017-09-08 | 桑诺维恩药品公司 | 杂芳基化合物及其使用方法 |
| CN103476757A (zh) | 2011-02-18 | 2013-12-25 | 阿勒根公司 | 作为磷酸二酯酶10(pde10a)的抑制剂的取代的6,7-二烷氧基-3-异喹啉醇衍生物 |
| AU2012249421B9 (en) | 2011-04-28 | 2015-10-22 | Novartis Ag | 17alpha-hydroxylase/C17,20-lyase inhibitors |
| WO2013047411A1 (ja) * | 2011-09-29 | 2013-04-04 | 富士フイルム株式会社 | 新規なトリアジン誘導体、紫外線吸収剤 |
| EP2828262A4 (en) | 2012-03-19 | 2015-09-23 | Forum Pharmaceuticals Inc | IMIDAZOTRIAZINONVERBINDUNGEN |
| JP6215315B2 (ja) | 2012-06-12 | 2017-10-18 | アッヴィ・インコーポレイテッド | ピリジノンおよびピリダジノン誘導体 |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| WO2014071044A1 (en) | 2012-11-01 | 2014-05-08 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a) |
| TW201512201A (zh) * | 2013-03-14 | 2015-04-01 | Forum Pharmaceuticals Inc | 化合物的多晶型及鹽類 |
| US9464076B2 (en) | 2013-03-15 | 2016-10-11 | Daiichi Sankyo Company, Limited | Benzothiophene derivative |
| TWI634114B (zh) * | 2013-05-08 | 2018-09-01 | 永恒生物科技公司 | 作為激酶抑制劑之呋喃酮化合物 |
| SG11201509186TA (en) | 2013-06-27 | 2016-01-28 | Pfizer | Heteroaromatic compounds and their use as dopamine d1 ligands |
| WO2015006689A1 (en) | 2013-07-12 | 2015-01-15 | University Of South Alabama | Treatment and diagnosis of cancer and precancerous conditions using pde10a inhibitors and methods to measure pde10a expression |
| US9200016B2 (en) | 2013-12-05 | 2015-12-01 | Allergan, Inc. | Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) |
| MX382781B (es) | 2014-04-02 | 2025-03-13 | Intermune Inc | Piridinonas anti-fibroticas. |
| CN104211638A (zh) * | 2014-08-13 | 2014-12-17 | 李增 | 一种脂肪氨基取代的芸香碱类衍生物及其制备和作为抗阿尔兹海默症的药物中的应用 |
| CN104610134B (zh) * | 2015-01-29 | 2017-01-25 | 安徽星宇化工有限公司 | 一种6‑甲基‑2‑吡啶基甲醇的制备方法 |
| US10738035B2 (en) | 2015-05-13 | 2020-08-11 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| US10179131B2 (en) * | 2015-07-13 | 2019-01-15 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| JP6904970B2 (ja) | 2016-03-07 | 2021-07-21 | エナンタ ファーマシューティカルズ インコーポレイテッド | Ｂ型肝炎抗ウイルス剤 |
| US11124509B2 (en) | 2017-03-23 | 2021-09-21 | Clavius Pharmaceuticals, LLC. | Tri-substituted imidazoles for the inhibition of TGF beta and methods of treatment |
| EP3612522A4 (en) | 2017-04-18 | 2021-07-07 | Celgene Quanticel Research, Inc. | THERAPEUTIC COMPOUNDS |
| US10952978B2 (en) | 2017-08-28 | 2021-03-23 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| US11058678B2 (en) | 2018-01-22 | 2021-07-13 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| WO2019191166A1 (en) | 2018-03-29 | 2019-10-03 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| US12077548B2 (en) | 2018-08-22 | 2024-09-03 | Clavius Pharmaceuticals, LLC. | Substituted imidazoles for the inhibition of TGF-β and methods of treatment |
| UY38383A (es) | 2018-09-21 | 2020-04-30 | Enanta Pharm Inc | Heterociclos funcionalizados como agentes antivirales |
| US11198693B2 (en) | 2018-11-21 | 2021-12-14 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
| WO2020113094A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| WO2020247444A1 (en) | 2019-06-03 | 2020-12-10 | Enanta Pharmaceuticals, Inc, | Hepatitis b antiviral agents |
| WO2020247561A1 (en) | 2019-06-04 | 2020-12-10 | Enanta Pharmaceuticals, Inc, | Hepatitis b antiviral agents |
| WO2020247575A1 (en) | 2019-06-04 | 2020-12-10 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| US11738019B2 (en) | 2019-07-11 | 2023-08-29 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| US11236108B2 (en) | 2019-09-17 | 2022-02-01 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
| KR102811543B1 (ko) | 2019-10-16 | 2025-05-23 | 삼성디스플레이 주식회사 | 유기 전계 발광 소자 및 유기 전계 발광 소자용 다환 화합물 |
| WO2021188414A1 (en) | 2020-03-16 | 2021-09-23 | Enanta Pharmaceuticals, Inc. | Functionalized heterocyclic compounds as antiviral agents |
| TW202304303A (zh) * | 2021-04-13 | 2023-02-01 | 美商富曼西公司 | 殺真菌之吡啶酮 |
| WO2023059224A1 (en) | 2021-10-09 | 2023-04-13 | Joint Stock Company "Pharmasyntez" | A new class of antiviral drugs |
| US11993580B1 (en) | 2022-12-02 | 2024-05-28 | Neumora Therapeutics, Inc. | Methods of treating neurological disorders |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| YU4403A (sh) * | 2000-07-27 | 2006-05-25 | F. Hoffmann-La Roche Ag. | Derivati 3-indolil-4-fenil-1h-pirol-2,5-diona, kao inhibitori glikogen sintaza kinaze-3 beta |
| US20030032579A1 (en) | 2001-04-20 | 2003-02-13 | Pfizer Inc. | Therapeutic use of selective PDE10 inhibitors |
| EP1541149A1 (en) | 2002-06-26 | 2005-06-15 | Kyowa Hakko Kogyo Co., Ltd. | Phosphodiesterase inhibitor |
| UA86283C2 (uk) * | 2005-01-07 | 2009-04-10 | Пфайзер Продактс Инк. | Гетероароматичні сполуки хіноліну і їх застосування як інгібіторів pde10 |
| JP2007145819A (ja) * | 2005-10-28 | 2007-06-14 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
| NL2000397C2 (nl) | 2006-01-05 | 2007-10-30 | Pfizer Prod Inc | Bicyclische heteroarylverbindingen als PDE10 inhibitoren. |
| EP1845098A1 (en) | 2006-03-29 | 2007-10-17 | Ferrer Internacional, S.A. | Imidazo[1,2-b]pyridazines, their processes of preparation and their use as GABA receptor ligands |
| JP2009535394A (ja) | 2006-05-02 | 2009-10-01 | ファイザー・プロダクツ・インク | Ｐｄｅ１０阻害剤としての二環式ヘテロアリール化合物 |
| WO2008033455A2 (en) | 2006-09-13 | 2008-03-20 | The Institutes For Pharmaceutical Discovery, Llc | Biphenyl and heteroaryl phenyl derivatives as protein tyrosine phosphatases inhibitors |
| JP5079011B2 (ja) * | 2006-10-19 | 2012-11-21 | エフ．ホフマン−ラ ロシュ アーゲー | 糖尿病のための１１β−ＨＳＤ１阻害剤としてのイミダゾロン及びイミダゾリジノン誘導体 |
| FR2928924B1 (fr) | 2008-03-21 | 2010-04-23 | Sanofi Aventis | Derives polysubstitues de 6-heteroaryle-imidazo°1,2-a! pyridines, leur preparation et leur application en therapeutique |
| CN102131801B (zh) | 2008-06-25 | 2015-04-08 | 福拉姆医药股份有限公司 | 1,2-二取代的杂环化合物 |
| KR101662699B1 (ko) | 2009-05-07 | 2016-10-05 | 포럼 파마슈티칼즈 인크. | 페녹시메틸 헤테로고리 화합물 |
| IN2012DN02493A (https=) | 2009-09-03 | 2015-08-28 | Allergan Inc | |
| ES2879314T3 (es) | 2010-08-18 | 2021-11-22 | Biosplice Therapeutics Inc | Dicetonas e hidroxicetonas como activadores de la vía de señalización de catenina |
-
2009
- 2009-06-24 CN CN200980133288.7A patent/CN102131801B/zh not_active Expired - Fee Related
- 2009-06-24 JP JP2011516574A patent/JP5658664B2/ja not_active Expired - Fee Related
- 2009-06-24 US US12/490,808 patent/US8071595B2/en not_active Expired - Fee Related
- 2009-06-24 CA CA2729259A patent/CA2729259A1/en not_active Abandoned
- 2009-06-24 BR BRPI0914772A patent/BRPI0914772A2/pt not_active IP Right Cessation
- 2009-06-24 KR KR1020117001942A patent/KR20110031355A/ko not_active Abandoned
- 2009-06-24 MX MX2011000175A patent/MX2011000175A/es active IP Right Grant
- 2009-06-24 WO PCT/US2009/048426 patent/WO2009158393A1/en not_active Ceased
- 2009-06-24 AU AU2009262241A patent/AU2009262241B2/en not_active Ceased
- 2009-06-24 EP EP09770926.5A patent/EP2297133B1/en active Active
- 2009-06-25 EP EP09771005A patent/EP2303863A1/en not_active Withdrawn
- 2009-06-25 MX MX2011000176A patent/MX2011000176A/es not_active Application Discontinuation
- 2009-06-25 CN CN2009801332730A patent/CN102131800A/zh active Pending
- 2009-06-25 KR KR1020117001893A patent/KR20110029153A/ko not_active Withdrawn
- 2009-06-25 CA CA2729275A patent/CA2729275A1/en not_active Abandoned
- 2009-06-25 TW TW098121521A patent/TWI458723B/zh not_active IP Right Cessation
- 2009-06-25 JP JP2011516650A patent/JP2011526295A/ja active Pending
- 2009-06-25 AU AU2009262156A patent/AU2009262156A1/en not_active Abandoned
- 2009-06-25 BR BRPI0913958A patent/BRPI0913958A2/pt not_active IP Right Cessation
- 2009-06-25 US US13/001,359 patent/US8481534B2/en not_active Expired - Fee Related
- 2009-06-25 WO PCT/US2009/048617 patent/WO2009158473A1/en not_active Ceased
- 2009-06-25 TW TW103127120A patent/TWI542590B/zh not_active IP Right Cessation
-
2011
- 2011-11-07 US US13/290,527 patent/US8466148B2/en not_active Expired - Fee Related
-
2013
- 2013-06-17 US US13/919,516 patent/US20140038965A1/en not_active Abandoned
- 2013-06-17 US US13/919,320 patent/US8933074B2/en not_active Expired - Fee Related
-
2014
- 2014-10-31 US US14/529,435 patent/US9265767B2/en not_active Expired - Fee Related
- 2014-11-28 JP JP2014241945A patent/JP5820921B2/ja not_active Expired - Fee Related
- 2014-12-19 US US14/576,550 patent/US20150344467A1/en not_active Abandoned
-
2015
- 2015-10-05 JP JP2015197316A patent/JP2016014061A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011526295A5 (https=) | ||
| JP2011526282A5 (https=) | ||
| JP7794989B2 (ja) | Ｐａｒｐ１阻害薬及びその使用 | |
| JP6059342B2 (ja) | ｃ−ＭＥＴチロシンキナーゼ阻害剤として有用な新規な縮合ピリジン誘導体 | |
| CN101848895B (zh) | 血管新生抑制物质和抗肿瘤性铂络合物的组合使用 | |
| EP4497438B1 (en) | Tricyclic parp1 inhibitors and uses thereof | |
| BR112015006686B1 (pt) | Combinação de regorafenib e ácido acetilsalicílico para tratamento de câncer coloretal | |
| US20050032786A1 (en) | 1, 3-benzothiazinone derivatives and use thereof | |
| JP2011517443A5 (https=) | ||
| KR20120075481A (ko) | 치료적 유용성을 갖는 수용체 조절제로서 쿠마린 화합물 | |
| CA2642835C (en) | Salt of sulfinylbenzimidazole compound, and crystal and amorphous form thereof | |
| JP2003513066A5 (https=) | ||
| RU2002114041A (ru) | N-гуанидиноалкиламиды, их получение, их применение и содержащие их фармацевтические препараты | |
| CN106117182A (zh) | 喹唑啉‑n‑苯乙基四氢异喹啉类化合物及其制备方法和应用 | |
| CN110156783A (zh) | 作为pi3k/mtor抑制剂的嘧啶基取代的稠合喹啉化合物 | |
| JP2012526054A (ja) | 複素環置換のジフェニル尿素類誘導体及びその用途 | |
| CA2813153C (en) | 4-(methylaminophenoxy) pyrdin-3-yl-benzamide derivatives for treating cancer | |
| CN113766914B (zh) | 戊烷脒的类似物和其用途 | |
| TW202043209A (zh) | Mek抑制劑及其在醫藥上的應用 | |
| CN102850364B (zh) | 鬼臼衍生物及其组合物、制备方法和应用 | |
| JP2009073743A (ja) | 新規な縮合環式ピリミジン化合物又はその塩、及びその医薬組成物 | |
| TW201815773A (zh) | 酚噻嗪化合物及其用途 | |
| CA2562812A1 (en) | Imidazopyridine compound | |
| JP2011509994A5 (https=) | ||
| CN105085382B (zh) | 吡仑帕奈异构体晶型及其制备方法和用途 |